Evidence map›Paper›PMID 27103785›Full record

ArticleDrug design, development and therapy2016

Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.

Venkata Raveendra Pothineni, Dhananjay Wagh, Mustafeez Mujtaba Babar, Mohammed Inayathullah, David Solow-Cordero, Kwang-Min Kim, Aneesh V Samineni, Mansi B Parekh, Lobat Tayebi, Jayakumar Rajadas

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03891667 (Disulfiram), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03891667 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Disulfiram ("Antabuse"): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease

TypeinterventionalSponsorResearch Foundation for Mental Hygiene, Inc.Ran2019 to 2022Enrolled11ConditionsFatigue, Quality of LifeArmsDisulfiram
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. CCL17 Influences Borrelia burgdorferi Infection in the Heart.The Journal of infectious diseases · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Disulfiram: Mechanisms, Applications, and Challenges.Antibiotics (Basel, Switzerland) · 2023
    Review
  11. Disulfiram-Mitigating Unintended Effects.Antibiotics (Basel, Switzerland) · 2023
    Review
  12. Neuropsychiatric Symptoms and Tick-Borne Diseases.Current topics in behavioral neurosciences · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Venkata Raveendra PothineniBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Dhananjay WaghBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Mustafeez Mujtaba BabarBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Mohammed InayathullahBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
David Solow-CorderoChemical & Systems Biology, Stanford University School of Medicine, Stanford, CA, USA.
Kwang-Min KimBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Aneesh V SamineniBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Mansi B ParekhBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Lobat TayebiDepartment of Developmental Sciences, Marquette University School of Dentistry, Milwaukee, WI, USA.
Jayakumar RajadasBiomaterials and Advanced Drug Delivery Laboratory, Stanford Cardiovascular Pharmacology Division, Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Cardiovascular Institute of the South · USStanford University · USMarquette University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%-20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies.

Indexed as

High-Throughput Screening AssaysAnti-Bacterial AgentsBorrelia burgdorferiDose-Response Relationship, DrugHumansLyme DiseaseMicrobial Sensitivity TestsSmall Molecule LibrariesStructure-Activity RelationshipAnti-Bacterial AgentsSmall Molecule LibrariesBacTiter-Glo assayBorrelia burgdorferihigh-throughput screeningLyme diseasepersisters

Identifiers

PMID27103785
PMCPMC4827596
OpenAlexW2333899172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.